Heme Metabolism: Key Topics

Heme metabolism is a core biochemistry/hematology topic that shows up constantly in physiology, pharmacology, and clinical medicine (anemia, jaundice, porphyria, lead toxicity). Here are the topics that matter most, organized the way they're usually tested and applied clinically.

1. Heme Structure

Heme = protoporphyrin IX (a tetrapyrrole ring of 4 pyrrole rings joined by methenyl bridges, type III side-chain arrangement) + one Fe²⁺ ion coordinated at the center. It's the prosthetic group for hemoglobin, myoglobin, cytochromes (including cytochrome P450), catalase, and peroxidases (Biochemistry, 8th ed - Lippincott Illustrated Reviews, p. 781; Basic Medical Biochemistry, p. 1520).

2. Heme Biosynthesis Pathway

Occurs mainly in the liver (variable rate, feeds CYP450 demand) and erythroid bone marrow (constant rate, matched to globin synthesis). Straddles mitochondria and cytosol:

Step 1 (rate-limiting, mitochondrial): Glycine + succinyl-CoA → δ-aminolevulinic acid (ALA), catalyzed by ALA synthase (ALAS), requiring pyridoxal phosphate (vitamin B6).
ALA moves to cytosol → porphobilinogen (PBG) via ALA dehydratase (inhibited by lead) → uroporphyrinogen → coproporphyrinogen (successive decarboxylations/oxidations).
Coproporphyrinogen re-enters mitochondria → protoporphyrin IX.
Final step: ferrochelatase inserts Fe²⁺ into protoporphyrin IX to form heme (also inhibited by lead).

(Basic Medical Biochemistry - A Clinical Approach, 6e, p. 1520-1527; Biochemistry 8e Lippincott, p. 781-784)

3. Regulation of Heme Synthesis

There are two ALAS isoforms: ALAS1 (hepatic, housekeeping) is repressed and allosterically inhibited by free heme itself — classic negative feedback. Drugs that induce hepatic CYP450 (e.g., phenobarbital, many others) consume heme, dropping free heme levels and de-repressing ALAS1 — this is why certain drugs precipitate acute porphyria attacks. ALAS2 (erythroid) is regulated instead by iron availability (via IRE/IRP mRNA stability mechanisms), matching heme production to iron supply for hemoglobinization.
Heme also stabilizes the ribosomal initiation complex for globin synthesis, coordinating heme and globin production.

(Basic Medical Biochemistry, p. 1527; Biochemistry 8e Lippincott, p. 784)

4. Porphyrias — Clinical Correlation

Each porphyria results from a partial deficiency of a specific heme-synthesis enzyme, causing accumulation of the precursor just before the block:

Acute intermittent porphyria (PBG deaminase deficiency) — neuropsychiatric attacks, no photosensitivity.
Porphyria cutanea tarda (uroporphyrinogen decarboxylase deficiency) — most common porphyria, cutaneous photosensitivity.
Variegate porphyria, hereditary coproporphyria — mixed neuro-visceral and cutaneous features.
Congenital erythropoietic porphyria, hepatoerythropoietic porphyria — severe cutaneous disease.

Accumulated porphyrinogens/porphyrins cause either neurovisceral symptoms (colorless precursors like ALA/PBG) or photosensitivity (oxidized colored porphyrins that generate reactive oxygen species in skin on light exposure).

5. Heme Degradation and Bilirubin Metabolism

This is the pathway most tested clinically (jaundice work-ups):

Senescent RBCs (~120-day lifespan) phagocytosed by reticuloendothelial macrophages (spleen, liver, marrow).
Heme oxygenase cleaves heme → biliverdin + CO + Fe²⁺ (iron recycled to ferritin/transferrin).
Biliverdin reductase reduces biliverdin → unconjugated (indirect) bilirubin.
Unconjugated bilirubin travels bound to albumin to the liver.
Hepatocytes take it up, and UDP-glucuronosyltransferase (UGT1A1) conjugates it with glucuronic acid → conjugated (direct) bilirubin, which is water-soluble.
Conjugated bilirubin excreted into bile → intestine → gut bacteria convert it to urobilinogen → some reabsorbed (enterohepatic circulation, some excreted in urine as urobilin) → most oxidized to stercobilin (stool color).

(Basic Medical Biochemistry, p. 1527; Harrison's Principles of Internal Medicine 22E, "Bilirubin Metabolism"; Ganong's Review of Medical Physiology, 26e)

6. Clinical Disorders Tied to This Pathway

Jaundice classification: prehepatic (hemolysis → unconjugated hyperbilirubinemia), hepatic (impaired conjugation/uptake), post-hepatic/obstructive (conjugated hyperbilirubinemia, e.g., biliary obstruction).
Gilbert syndrome / Crigler-Najjar syndrome: reduced UGT1A1 activity → unconjugated hyperbilirubinemia.
Lead poisoning: inhibits ALA dehydratase and ferrochelatase → microcytic anemia with basophilic stippling, elevated ALA and free erythrocyte protoporphyrin.
Sideroblastic anemia: defective heme synthesis (often ALAS2 mutations or B6 deficiency) → ringed sideroblasts, iron-loaded mitochondria.
Iron-heme interplay: hepcidin, transferrin, ferritin, and IRE/IRP regulation link systemic iron status directly to erythroid heme synthesis.

Suggested study priority

If you need to rank these for exam or clinical relevance: (1) the synthesis pathway with ALAS as rate-limiting/regulated step, (2) heme degradation to bilirubin and jaundice classification (highest clinical yield), (3) porphyria enzyme-defect correlations, (4) lead poisoning mechanism, (5) iron-heme regulatory crosstalk.

If you want, I can go deeper into any single one of these (e.g., a full porphyria enzyme-defect table, or the bilirubin lab interpretation for jaundice) with more detail and diagrams.

This is a shared conversation. Sign in to Orris to start your own chat.